These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31619586)

  • 1. Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging.
    Mazur C; Powers B; Zasadny K; Sullivan JM; Dimant H; Kamme F; Hesterman J; Matson J; Oestergaard M; Seaman M; Holt RW; Qutaish M; Polyak I; Coelho R; Gottumukkala V; Gaut CM; Berridge M; Albargothy NJ; Kelly L; Carare RO; Hoppin J; Kordasiewicz H; Swayze EE; Verma A
    JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31619586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
    Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
    Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-cell map of antisense oligonucleotide activity in the brain.
    Mortberg MA; Gentile JE; Nadaf NM; Vanderburg C; Simmons S; Dubinsky D; Slamin A; Maldonado S; Petersen CL; Jones N; Kordasiewicz HB; Zhao HT; Vallabh SM; Minikel EV
    Nucleic Acids Res; 2023 Aug; 51(14):7109-7124. PubMed ID: 37188501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic modeling for hepatic delivery and efficacy of antisense oligonucleotides with lipophilic ligands in mice.
    Watanabe A; Katsube T
    Biopharm Drug Dispos; 2021 Apr; 42(4):178-187. PubMed ID: 33724506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.
    Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA
    Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
    Paton DM
    Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration.
    Jafar-Nejad P; Powers B; Soriano A; Zhao H; Norris DA; Matson J; DeBrosse-Serra B; Watson J; Narayanan P; Chun SJ; Mazur C; Kordasiewicz H; Swayze EE; Rigo F
    Nucleic Acids Res; 2021 Jan; 49(2):657-673. PubMed ID: 33367834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier.
    Barker SJ; Thayer MB; Kim C; Tatarakis D; Simon MJ; Dial R; Nilewski L; Wells RC; Zhou Y; Afetian M; Akkapeddi P; Chappell A; Chew KS; Chow J; Clemens A; Discenza CB; Dugas JC; Dwyer C; Earr T; Ha C; Ho YS; Huynh D; Lozano EI; Jayaraman S; Kwan W; Mahon C; Pizzo M; Robles-Colmenares Y; Roche E; Sanders L; Stergioulis A; Tong R; Tran H; Zuchero Y; Estrada AA; Gadkar K; Koth CMM; Sanchez PE; Thorne RG; Watts RJ; Sandmann T; Kane LA; Rigo F; Dennis MS; Lewcock JW; DeVos SL
    Sci Transl Med; 2024 Aug; 16(760):eadi2245. PubMed ID: 39141703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain.
    Mohan A; Fitzsimmons B; Zhao HT; Jiang Y; Mazur C; Swayze EE; Kordasiewicz HB
    Pain; 2018 Jan; 159(1):139-149. PubMed ID: 28976422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides.
    Dastpeyman M; Sharifi R; Amin A; Karas JA; Cuic B; Pan Y; Nicolazzo JA; Turner BJ; Shabanpoor F
    Int J Pharm; 2021 Apr; 599():120398. PubMed ID: 33640427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice.
    Shimizu R; Kitade M; Kobayashi T; Hori S; Watanabe A
    J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):67-77. PubMed ID: 25376372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system.
    Sullivan JM; Mazur C; Wolf DA; Horky L; Currier N; Fitzsimmons B; Hesterman J; Pauplis R; Haller S; Powers B; Tayefeh L; DeBrosse-Serra B; Hoppin J; Kordasiewicz H; Swayze EE; Verma A
    J Transl Med; 2020 Aug; 18(1):309. PubMed ID: 32771027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Save Your Maximum Tolerated Dose: How to Diagnose Procedure-Related Spinal Cord Lesions After Lumbar Intrathecal Bolus Administration of Oligonucleotides in Cynomolgus Monkeys.
    Korte S; Luft J; von Keutz A; Runge F; Mecklenburg L; Wozniak MM; Zander S; Ludwig FT; Pajaziti B; Romeike A; Korytko P
    Int J Toxicol; 2020; 39(6):510-517. PubMed ID: 32856507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a simple, rapid, and robust intrathecal catheterization method in the rat.
    Mazur C; Fitzsimmons B; Kamme F; Nichols B; Powers B; Wancewicz E
    J Neurosci Methods; 2017 Mar; 280():36-46. PubMed ID: 28163066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
    Biliouris K; Gaitonde P; Yin W; Norris DA; Wang Y; Henry S; Fey R; Nestorov I; Schmidt S; Rogge M; Lesko LJ; Trame MN
    CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):581-592. PubMed ID: 30043511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
    Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
    J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc
    Wang Y; Yu RZ; Henry S; Geary RS
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):475-485. PubMed ID: 31144994
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.